A phase II trial of irinotecan in hormone-refractory prostate cancer

Investigational New Drugs

Volumn 16, Issue 4, 1998, Pages 353-359

  Reese, David M ^a,b   Tchekmedyian, Simon ^a   Chapman, Yvonne ^a   Prager, Diane ^a   Rosen, Peter J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical trial; Irinotecan; Prostate cancer; Topoisomerase I

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; IRINOTECAN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0032457860     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006120910380     Document Type: Article

References (21)

1. Small EJ, Vogelzang NJ: Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm. J Clin Oncol 15: 382-388, 1997
2. Perry CM, McTavish D: Estramustine phosphate sodium: A review of its pharmacodynamics and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging 7: 49-74, 1995
3. Small EJ, Marshall ME, Reyno L, Meyers R, Natale R, Meyer M, Lenehan P, Chen L, Eisenberger M: Superiority of suramin + hydrocortisone (S + H) over placebo + hydrocortisone (P + H): Results of a multi-center double-blind phase ni study in patients with hormone refractory prostate cancer (HRPC) (abstract). Proc Am Assoc Clin Oncol 17: 308a, 1998
4. Wasalenko JK, Dawson NA: Management of progressive metastatic prostate cancer. Oncology 11: 1551-1560, 1997
5. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14: 1756-1764, 1996
6. Hudes GR, Greenberg R, Krigel RL, Fox S, Scher R, Litwin S, Watts P, Speicker L, Tew K, Comis R: Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 10: 1754-1761, 1992
7. Pienta KJ, Redman B, Hussain M, Cummings G, Esper PS, Appel C, Flaherty LE: Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12: 2005-2012, 1994
8. Hudes GR, Nathan F, Khater C, Haas N, Cornfield M, Giantonio B, Greenberg R, Gomella L, Litwin S, Ross E, Roethke S, McAleer C: Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 15: 3156-3163, 1997
9. Shelton G, Gerson H, Zuech N, Bagliella E, Benson M, Sawczuk I, Olsson C, Petrylak D: Activity of docetaxel (D) + estramustine (E) after dexamethasone (dex) treatment in patients with androgen insensitive prostate cancer (abstract). Proc Am Soc Clin Oncol 17: 343a, 1998
10. Hsiang YH, Liu LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48: 1722-1726, 1988
11. Kawato Y, Furuta T, Aonuma M: Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 28: 192-198, 1991
12. Rougier R, Bugart R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with flourouracil-based chemotherapy. J Clin Oncol 15: 251-260, 1997
13. Lievano G, Mirochnik Y, Rubenstein M, Shaw M, Guinan P: Antitumor effect of CPT-11, a new derivative of camptothecin, against human prostate cancer (PC-3) in vitro and prostate rat tumor (AT-3) in vivo: Methods Findings Exp Pharmacol 18: 659-662, 1996
14. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD: Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11: 1566-1572, 1993
15. Smith DC, Dunn RL, Strawderman MS, Pienta KJ: Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 16: 1835-1843, 1998
16. Small EJ, Srinivas S, Egan B, McMillan A, Rearden JP: Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer. J Clin Oncol 14: 1617-1625, 1996
17. Sella A, Kilbourn R, Amato R, Bui C, Zukiwski A, Ellerhorst J, Logothetis CJ: Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 12: 683-688, 1994
18. Colleoni M, Graiff C, Vicario G, Nelli P, Sgarbossa G, Pancheri F, Manente P: Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer. Am J Clin Oncol 20: 383-386, 1997
19. Fields S, Burris H, Wilding G, Eckardt J, O'Rourke T, Rinaldi D, Snetzer J, Bigley T, Hohneller J, Von Hoff D: Evaluating the role of navelbine in hormone-refractory prostate cancer. Proc Am Soc Clin Oncol 13: 727, 1994
20. Moore MJ, Osoba D, Murphy K, Tannock IF, Armitage A, Findlay B, Coppin C, Neville A, Venner P, Wilson J: Use of palliative endpoints to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 12: 689-694, 1994
21. Hudes GR, Kosierowski R, Greenberg R, Ramsey HE, Fox SC, Ozols RF, McAleer CA, Giantonio BJ: Phase II study of topotecan in metastatic hormone-refractory prostate cancer. Invest New Drugs 13: 235-240, 1995